Opioid Withdrawal Treatment Claims Spur FDA's Latest Kratom Warnings
This article was originally published in The Rose Sheet
You may also be interested in...
Ohio's Proposed Ban On Sales Marks Kratom Industry's Latest Battlefront
Ohio Board of Pharmacy proposes placing into Schedule I kratom constituent ingredients mitragynine and 7-hydroxymitragynine, a change that would prohibit kratom sales in the state. The board's findings "parrot the false propaganda" of FDA in its "crusade to ban kratom," says the American Kratom Association.
US House Committee Requests Proof Of FDA Progress Seizing Opioids In International Mail
Energy & Commerce's Republican and Democrat leadership ask FDA Commissioner Scott Gottlieb about work by the agency's Office of Criminal Investigations focused on opioid drugs, the office's staffing and its priorities. They note FDA's FY2018 appropriation included $94m for its work in international mail facilities.
US House Committee Requests Proof Of FDA Progress Seizing Opioids In International Mail
Energy & Commerce's Republican and Democrat leadership ask FDA Commissioner Scott Gottlieb about work by the agency's Office of Criminal Investigations focused on opioid drugs, the office's staffing and its priorities. They note FDA's FY2018 appropriation included $94m for its work in international mail facilities.